NCT05841550View on ClinicalTrials.gov

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

May 19, 2027

Study Completion Date

May 19, 2035

Conditions
Multiple MyelomaSmoldering Multiple Myeloma
Interventions
BIOLOGICAL

TG01

All participants will receive the same treatment as described under arm

Trial Locations (1)

0450

RECRUITING

Oslo Myeloma Center, Oslo

All Listed Sponsors
collaborator

Targovax ASA

INDUSTRY

lead

Oslo University Hospital

OTHER